Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharmaceuticals Incorporated (LGND) - Total Assets
Latest total assets as of September 2025: $1.48 Billion USD
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) holds total assets worth $1.48 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ligand Pharmaceuticals Incorporated - Total Assets Trend (1994–2024)
This chart illustrates how Ligand Pharmaceuticals Incorporated’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ligand Pharmaceuticals Incorporated - Asset Composition Analysis
Current Asset Composition (December 2024)
Ligand Pharmaceuticals Incorporated's total assets of $1.48 Billion consist of 35.2% current assets and 64.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $42.45 Million | 4.5% |
| Inventory | $14.11 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $266.65 Million | 28.3% |
| Goodwill | $105.25 Million | 11.2% |
Asset Composition Trend (1994–2024)
This chart illustrates how Ligand Pharmaceuticals Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ligand Pharmaceuticals Incorporated's current assets represent 35.2% of total assets in 2024, a decrease from 89.1% in 1994.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 16.3% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 28.3% of total assets.
Ligand Pharmaceuticals Incorporated Competitors by Total Assets
Key competitors of Ligand Pharmaceuticals Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ligand Pharmaceuticals Incorporated - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ligand Pharmaceuticals Incorporated generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ligand Pharmaceuticals Incorporated is currently not profitable relative to its asset base.
Ligand Pharmaceuticals Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.69 | 12.49 | 5.00 |
| Quick Ratio | 24.30 | 11.95 | 4.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $723.38 Million | $ 284.62 Million | $ 400.45 Million |
Ligand Pharmaceuticals Incorporated - Advanced Valuation Insights
This section examines the relationship between Ligand Pharmaceuticals Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.76 |
| Latest Market Cap to Assets Ratio | 3.84 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | $941.77 Million |
| Market Capitalization | $3.62 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ligand Pharmaceuticals Incorporated's assets at a significant premium ( 3.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ligand Pharmaceuticals Incorporated's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ligand Pharmaceuticals Incorporated (1994–2024)
The table below shows the annual total assets of Ligand Pharmaceuticals Incorporated from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $941.77 Million | +19.63% |
| 2023-12-31 | $787.22 Million | +3.22% |
| 2022-12-31 | $762.67 Million | -41.22% |
| 2021-12-31 | $1.30 Billion | -4.75% |
| 2020-12-31 | $1.36 Billion | -8.87% |
| 2019-12-31 | $1.49 Billion | +18.57% |
| 2018-12-31 | $1.26 Billion | +87.89% |
| 2017-12-31 | $671.02 Million | +11.54% |
| 2016-12-31 | $601.59 Million | +12.67% |
| 2015-12-31 | $533.93 Million | +106.93% |
| 2014-12-31 | $258.03 Million | +146.42% |
| 2013-12-31 | $104.71 Million | +0.43% |
| 2012-12-31 | $104.26 Million | -14.79% |
| 2011-12-31 | $122.35 Million | +61.93% |
| 2010-12-31 | $75.56 Million | -33.54% |
| 2009-12-31 | $113.70 Million | -33.68% |
| 2008-12-31 | $171.45 Million | -1.06% |
| 2007-12-31 | $173.28 Million | -46.86% |
| 2006-12-31 | $326.05 Million | +3.63% |
| 2005-12-31 | $314.62 Million | -5.37% |
| 2004-12-31 | $332.47 Million | +10.36% |
| 2003-12-31 | $301.25 Million | +11.32% |
| 2002-12-31 | $270.61 Million | +130.36% |
| 2001-12-31 | $117.47 Million | +3.57% |
| 2000-12-31 | $113.42 Million | -15.73% |
| 1999-12-31 | $134.60 Million | -13.72% |
| 1998-12-31 | $156.00 Million | +45.25% |
| 1997-12-31 | $107.40 Million | +5.19% |
| 1996-12-31 | $102.10 Million | +9.08% |
| 1995-12-31 | $93.60 Million | +100.43% |
| 1994-12-31 | $46.70 Million | -- |